Your session is about to expire
← Back to Search
FORE8394 for Advanced Unresectable Cancer
Study Summary
This trial is testing a new cancer drug to see if it is safe and effective.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My glioma has a specific BRAF mutation and I haven't been treated with BRAF, MEK, or ERK inhibitors.I haven't had major surgery or significant injury within the last 14 days.I do not have any unmanaged ongoing illnesses.I have a serious heart condition.My advanced cancer has not responded to, came back after, or I couldn't tolerate standard treatments, or there are no standard treatments available.My solid tumor is caused by a specific BRAF mutation and I haven't had BRAF therapy.My advanced cancer is caused by a specific BRAF mutation and I haven't been treated with BRAF, MEK, or ERK inhibitors.My cancer has RAS mutations or RTK activation.I have colorectal or pancreatic cancer.I have severe nausea, vomiting, or issues absorbing food due to my condition.I am 10 years or older and weigh at least 30 kg.My brain tumor is classified as high grade (Grade 3 or 4) or low grade.I am fully active or can carry out light work.I have another cancer, but it's under control and not expected to affect this study.I finished my last cancer treatment more than 2 weeks ago.I am not infected with HIV, HBV, or HCV.My solid tumor is caused by a specific BRAF mutation and I haven't had BRAF-targeted treatment.My blood, liver, and kidney functions are all within normal ranges.I am not pregnant and agree to use birth control during and up to 3 months after the study.
- Group 1: FORE8394
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there other research facilities conducting this experiment within the state?
"9 clinical trial sites are available for this study, which include major medical centres such as Capital Regional Medical Center in Jefferson City and MD Anderson Cancer Center in Houston. There are also 6 other locations besides these two."
Are volunteers still being accepted for this research project?
"This trial, which was first announced on April 1st, 2015, is still recruiting patients according to the latest information available on clinicaltrials.gov."
Are there any other investigations that have been carried out with FORE8394?
"As of now, there is only 1 study underway for FORE8394. However, none of the live studies are in Phase 3 yet. The majority of research sites for this clinical trial are located in Scottsdale, Arizona; however, there are a total 17 locations running trials for FORE8394 across the United States."
How many individuals are a part of this research program?
"One hundred individuals that meet the study's inclusion criteria are necessary to carry out the planned research. The sponsor, Fore Biotherapeutics, will be conducting the trial at Capital Regional Medical Center in Jefferson City, Missouri and MD Anderson Cancer Center in Houston, Texas among other sites."
Have similar studies been undertaken before?
"The most recent clinical trial for FORE8394 was in 2015 and, to date, only one trial has been conducted. The international study, sponsored by Fore Biotherapeutics, recruited 100 participants and completed both Phase 1 & 2 of drug approval."
Share this study with friends
Copy Link
Messenger